Compare Bristol-Myers Squibb Co (BMY) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fubotv Inc — how do they compare? Bristol-Myers Squibb Co trades at $60.32 (market cap $119.91B), while Fubotv Inc trades at $10.15 (market cap $302.39M). The key difference: Bristol-Myers Squibb Co is far larger — about 396.5× Fubotv Inc's market cap, and Bristol-Myers Squibb Co pays a 4.29% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| BMY | FUBO | |
|---|---|---|
Market Cap | $119.91B | $302.39M |
Sector | Health | Technology |
52-Week High | $62.37 | $54.72 |
52-Week Low | $42.60 | $8.09 |
Enterprise Value | $155.85B | $472.81M |
Dividend Yield | 4.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.69, up 4.81% on the day, near the consensus price target of $60.00. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters. Fundamentally, the company maintains strong profitability with a 70.46% gross margin and 15.01% net margin, though it faces a patent cliff. Recent FDA acceptance of its new drug application for mezigdomide highlights pipeline progress.
BMY presents a balanced outlook with a solid dividend yield and attractive valuation multiples, but investors must weigh growth from its oncology portfolio against patent expiration risks. Analyst sentiment is mixed, with nearly equal buy and hold ratings, reflecting cautious optimism amid competitive and regulatory pressures.
FUBO stock trades at $10.46, up 9.64% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals, with revenue reaching $1.62B in 2024 and a projected net profit of $123M in 2025. Recent CEO appointment of former Disney+ executive Alisa Bowen has driven positive sentiment, while valuation ratios like P/E of 2.67 and P/S of 0.21 appear attractive relative to historical norms.
The outlook for FUBO is cautiously optimistic, with upside to the $16.25 consensus price target, but risks include persistent cash flow challenges and intense streaming competition. Investors should weigh the potential for profitability growth against execution risks in a crowded market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
